It is interesting to mention in this context that during FY23, achieved
the revenue fro^ operations, which stoodat Rs. 14,399.93 Lacs.
Dear Shareholders,
It's the time once again where I get to connect with our
shareholders/stakeholders. And connecting with shareholders/stakeholders is something I
always look forward to. I hope you are well.
With a rich history dating back to 1992, we have come to this business,
and completed its glorious 31 years.
Titan Biotech chasing of growth has always been driven by a strategic
focus on differentiation as well as relentless execution to deliver at scale and with
quality. Our strategy is always focus on the quality over the quantity.
Amid of The Russia- Ukraine conflict, which caused supply chain
disruptions worldwide, this financial year was a year of uninterrupted operations after
the preceding period of turmoil we came through and allowed us a full return to business
normalcy.
The business saw a steady growth, currently the total revenue increase
by 17% in this Financial Year 2023, clocking Rs.14,594.24 Lacs of total revenue.
We extend our gratitude to ouremployees, customers, and shareholders
for their continued support. Together, we will navigate the challenges and opportunities
to capitalise on those that lie ahead and realise our vision for aprosperous future.
Look forward to connecting with you again.
WARM REGARDS
NARESH KUMAR SINGLA MANAGING DIRECTOR